Sanofi is a diversified global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Our business includes pharmaceuticals, comprising prescription drugs, consumer healthcare and generics; vaccines and animal health.

• 2011 net sales: €33,389 million, +3.2% on a reported basis, +5.3% at constant exchange rates (CER) versus 2010
• 2011 business EPS: €6.65, -5.8% on a reported basis, -3.8% at CER versus 2010

Sanofi has identified key growth platforms: Emerging Markets (World excluding U.S., Canada, Western Europe, Japan, Australia and New Zealand), Human Vaccines, Consumer Health Care, Diabetes Solutions, New Products and Animal Health.

In April 2011, Sanofi realized the acquisition of Genzyme, a leading biotechnology company.

• 2011 consolidated net sales of growth platforms: €19,308 million, +10.8% at CER excluding A/H1N1 vaccines sales
• Genzyme sales consolidated since April 1st, 2011: €2,395 million, +7.7% on constant structure basis and at constant exchange rates
• Growth platforms and Genzyme represent 65% of total consolidated sales compared with 56.9% for 2010

* include Diabetes, Vaccines, Consumer Health Care and Animal Health sales generated in Emerging Market. 
** excluding A/H1N1sales, growth platforms sales increased 10.8%.
*** Multaq® et Jevtana®.

• 2011 net sales of the pharmaceuticals business: €27,890 million, +6.7% at CER

Sanofi's pharmaceuticals business notably focuses on diabetes, oncology, and other flagship products in thrombosis, cardiovascular, central nervous system, internal medicine areas. Since April 1st 2011, Sanofi’s pharmaceuticals business also includes Genzyme products.

Sanofi also has a significant presence in Consumer Health Care, in various product categories.

• 2011 net sales of Consumer Health Care: €2,666 million, +22.8% at CER

In addition, our pharmaceuticals portfolio comprises other prescription drugs including Generics.

• 2011 net sales of Generics: €1,746 million, +16.2% at CER

Sanofi Pasteur, the fully integrated vaccines business of Sanofi, is a world leader in the vaccines industry offering a large range of vaccines covering 20 different infectious diseases.

• 2011 net sales of the vaccines business: €3,469 million, - 5.5% at CER, +7.2% excluding A/H1N1 vaccines sales
• Non-consolidated 2011 sales of Sanofi Pasteur MSD (50/50 joint-venture with Merck): €791 million, -13.8% on a reported basis

Merial, a wholly owned subsidiary of Sanofi since September 18, 2009, is one of the world’s leading animal health companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners.

• 2011 sales of Merial: €2,030 million, +4.3% at CER

In 2011, Emerging Markets sales recorded double digit growth (up 12.4% to €507 million) accounting for 25.0% of total Merial sales.

Sanofi has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries. 

Sanofi is the established leader in Emerging Markets, holding top positions in the main countries. In 2011, Emerging Markets totaled €10,133 million, an increase of 10.4% (excluding Genzyme and A/H1N1 vaccines sales of €361 million booked in 2010). Emerging Markets sales contribute to 30.3% of the Groupe sales and become the most important contributors to the region sales.